Background

A lot of drug-eluting stents (DESs) are implanted every year around the world, but the problem of in-stent restenosis remains in interventional cardiology. Nowadays, the optimal approach to paclitaxel-eluting stent (PES) restenosis treatment is not clear.

Methods

During the period of January 2005–December 2006, we enrolled 112 patients who underwent sirolimus-eluting stent (SES) implantation for cases of PES restenosis in Sani Konukoglu Medical Center, Gaziantep, Turkey. We evaluated acute and 12-month angiographic and clinical outcomes through clinical examination or telephone contact.

Methods

During the period of January 2005–December 2006, we enrolled 112 patients who underwent sirolimus-eluting stent (SES) implantation for cases of PES restenosis in Sani Konukoglu Medical Center, Gaziantep, Turkey. We evaluated acute and 12-month angiographic and clinical outcomes through clinical examination or telephone contact.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Coronary stenting with MGuard: extended follow-up of first human trial
2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
3. Treatment of STEMI with neither PCI nor thrombolysis
4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree